MIRA biotech catalysts & pipeline

MIRA PHARMACEUTICALS INC · Data as of 2026-09-08

Upcoming catalysts

MIRA-55 — IND submission

Q1 2027

Subject to successful completion of the remaining IND-enabling studies, applicable regulatory requirements and other development considerations, the Company is targeting submission of an Investigational New Drug application for MIRA-55 to the U.S. Food and Drug Administration in the first quarter of 2027.

Source filing

MIRA-55 — NDA/BLA submission

Q1 2027

Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission

Source filing

Explore the free biotech catalyst calendar